RxDoctor Payments Data

Scott Steinberg, MD

Pulmonary Disease · Jacksonville, FLNPI 1326433624

Payments from drug & device makers

$564in general payments, 2019–2025

Across 13 payments — averaging $43.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$128
  • AstraZeneca$106
  • Philips North America LLC$74
  • Intuitive Surgical$63
  • Inogen, Inc.$40
  • Regeneron Healthcare Solutions, Inc.$37
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$564 in reported general payments places this provider in the 20th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$81,176
Medicare patients
333
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$159,825
Trelegy ElliptaFluticasone/Umeclidin/Vilanter206$158,394
Spiriva RespimatTiotropium Bromide30$19,156
Stiolto RespimatTiotropium Br/Olodaterol Hcl26$14,515
Breo ElliptaFluticasone/Vilanterol15$12,357
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,594
SymbicortBudesonide/Formoterol Fumarate24$7,695
Albuterol Sulfate HfaAlbuterol Sulfate97$2,949
Proair RespiclickAlbuterol Sulfate25$1,943
Wixela InhubFluticasone Propion/Salmeterol17$1,301
Ventolin HfaAlbuterol Sulfate19$1,051
Roflumilast11$456
Fluticasone Propionate19$343
Montelukast Sodium11$90
Prednisone18$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$25$193,49568 claims
GSKTrelegy Ellipta, Breo Ellipta$34$170,751221 claims
AstraZenecaBreztri Aerosphere, Symbicort$106$16,28936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →